Filing Summary: AzurRx BioPharma, Inc. Form 10-K
Entity and period: The supplied filing identifies AzurRx BioPharma, Inc., not Gridai Technologies Corp. It is an annual report for the fiscal year ended December 31, 2018; it does not provide standalone fourth-quarter results.
Business context and reporting period
AzurRx is a development-stage biotechnology company developing non-systemic biologics for gastrointestinal disorders. Its lead candidate, MS1819-SD, is being developed for exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis. AZX1101 and AZX1103 are preclinical beta-lactamase program candidates. The company reported no product revenue in 2018 or 2017.
Financial and operating metrics
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.99 million | $2.40 million |
| General and administrative expense | $8.24 million | $7.69 million |
| Operating loss | $13.43 million | $10.22 million |
| Net loss | $13.53 million | $11.10 million |
| Basic and diluted loss per share | $0.88 | $1.04 |
| Cash used in operating activities | $10.87 million | $7.18 million |
- Margins: Not meaningful; the company had no revenue.
- Liquidity at year-end: Cash was $1.11 million, working capital approximately $1.80 million, and current assets $4.80 million. Other receivables of $3.17 million included $2.16 million of French R&D tax credits, so reported current assets were not equivalent to cash on hand.
- Debt and liabilities: Year-end current liabilities were $3.00 million, including a $255,000 insurance-premium note payable. The 2017 LPC convertible debenture was repaid in July 2018. After year-end, the company borrowed $2.0 million through two senior convertible notes bearing 10% interest (potentially 6% if both were repaid before December 31, 2019), with repayment secured in part by tax credits.
- Cash and financing: Cash increased from $573,000 to $1.11 million. Financing activities provided $11.71 million, mainly from the May 2018 stock offering and warrant exercises. The May offering generated approximately $9.6 million net proceeds. Operating cash use increased year over year.
Material changes versus the prior year
- R&D expense rose by $2.59 million, primarily due to MS1819-SD clinical-trial milestones, new manufacturing batches, and startup of U.S. R&D operations.
- G&A expense increased by $551,000. Higher stock compensation and personnel costs were partly offset by lower professional fees.
- Net loss widened by $2.44 million, despite interest expense declining to $102,000 from $875,000 as the LPC debenture balance fell and was repaid.
- Operating cash use increased by $3.68 million. The filing attributes a significant working-capital use to increased receivables, including French tax credits and amounts billed to Mayoly.
- In December 2018, the company paid $1.55 million to acquire from Protea the rights to contingent milestone, royalty, and transaction-value payments under their prior agreement; consideration included $250,000 cash and $1.30 million in stock. This extinguished the recorded contingent-consideration liability.
Outlook, commentary, risks, and unusual items
- The Phase IIa MS1819-SD study in 11 chronic-pancreatitis patients reported a preplanned, per-protocol mean CFA increase of 21.8% at the highest dose (p=0.002); the filing cautions that the study was not powered for efficacy. FDA cleared an IND for a cystic-fibrosis study, initiated in late 2018, with approximately 30 patients and expected completion in 2019. The company announced first patient dosing in February 2019.
- Management expected to advance AZX1103 preclinical work and anticipated filing an IND in 2019; plans for AZX1101 were under assessment. These are expectations, not assured milestones.
- The company stated that recurring losses, negative operating cash flows, and dependence on external financing raised substantial doubt about its ability to continue as a going concern. The independent auditor’s opinion was unqualified but included a going-concern explanatory paragraph.
- Management expected continued substantial losses and rising development costs, and said additional capital would be required. Risks include clinical and regulatory failure or delay, patient enrollment, reliance on contract manufacturers and research organizations, competition, intellectual-property protection, and dilution or restrictive financing terms.
- After year-end, a March 2019 agreement with Mayoly transferred all rights to MS1819-SD to AzurRx. Consideration included €800,000 paid in stock, a further €1.5 million in scheduled cash and stock payments, assumed liabilities, and forgiveness of amounts Mayoly owed. Mayoly retained specified royalty-bearing commercialization rights in certain territories.
- The filing reports effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the issuer: this filing is for AzurRx BioPharma, Inc., not Gridai Technologies Corp.
- Review the going-concern disclosure and assess liquidity, timing and collection of French tax credits, and subsequent financing needs.
- Verify the terms, maturity triggers, collateral, conversion provisions, and related-party aspects of the $2.0 million ADEC notes, along with potential dilution.
- Track MS1819-SD trial enrollment, safety and efficacy results, regulatory milestones, and the full economic terms of the Mayoly asset purchase and retained royalties.
- Reconcile the filing’s investing-cash-flow presentation: the cash-flow statement reports $305,473 used in 2018, while MD&A states $305,573.